CPHI Annual Report: Continuous Manufacturing Will Alter the Drug Manufacturing Landscape a Decade from Now

18

The merits of Pharmaceutical Continuous Manufacturing (PCM) as a cost-effective tool for reshoring essential APIs and medicines are well known. It now also appears in the U.S.’ and many other countries’ preparedness strategy for supply chain shocks. Still, PCM is a topic that has been much maligned and debated over the last half century. PCM’s detractors cite a myriad of hurdles to implementation that they believe are too large to overcome for a risk-averse industry, but it is a mistake to look at barriers to PCM adoption in isolation. The industry is pursuing innovation in many areas and the skills and infrastructure required to make each innovation area will work together to lower the risk of adoption of any one initiative, including PCM.